StonvexLoading…
StonvexStonvexStonvexCore line items from SJM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-04-30 | Annual 2024 2024-04-30 | Annual 2023 2023-04-30 | Annual 2022 2022-04-30 |
|---|---|---|---|---|
Revenue | $8.73B | $8.18B | $8.53B | $8.00B |
Operating Income | $-673.90M | $1.31B | $157.50M | $1.02B |
Net Income | $-1.23B | $744.00M | $-91.30M | $631.70M |
EPS (Diluted) | $-11.57 | $7.13 | $-0.86 | $5.83 |
Total Assets | $17.56B | $20.27B | $14.99B | $16.05B |
Total Liabilities | $11.48B | $12.58B | $7.70B | $7.91B |
Cash & Equivalents | $69.90M | $62.00M | $655.80M | $169.90M |
Free Cash Flow OCF − CapEx | $816.60M | $642.90M | $717.00M | $718.80M |
Shares Outstanding | 106.43M | 106.19M | 104.40M | 106.46M |